MARKET

LPTX

LPTX

Leap Therapeutic
NASDAQ
0.3166
-0.0482
-13.21%
After Hours: 0.3109 -0.0057 -1.80% 19:57 03/28 EDT
OPEN
0.3385
PREV CLOSE
0.3648
HIGH
0.3490
LOW
0.3050
VOLUME
1.91M
TURNOVER
--
52 WEEK HIGH
4.790
52 WEEK LOW
0.3050
MARKET CAP
13.06M
P/E (TTM)
-0.1754
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 2d ago
HC Wainwright & Co. Reiterates Neutral on Leap Therapeuticsto Neutral
Benzinga · 2d ago
H.C. Wainwright Reaffirms Their Hold Rating on Leap Therapeutics (LPTX)
TipRanks · 2d ago
Leap Therapeutics Reports Positive Clinical Data and Financial Results
TipRanks · 2d ago
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
Benzinga · 3d ago
Leap Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 3d ago
Leap Therapeutics Reports Positive DeFianCe Phase 2 Data Of Sirexatamab In Colorectal Cancer
NASDAQ · 3d ago
Leap Therapeutics GAAP EPS of -$0.37 misses by $0.01
Seeking Alpha · 3d ago
More
About LPTX
More
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Recently
Symbol
Price
%Change

Webull offers Leap Therapeutics Inc stock information, including NASDAQ: LPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LPTX stock methods without spending real money on the virtual paper trading platform.